rupiya.io
⠋Loading...
0%
❯ Compiling peer comparison...
Brooks Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Brooks Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Sales | ₹77 Cr | ₹91 Cr | ₹63 Cr | ||
| Expenses | ₹77 Cr | ₹105 Cr | ₹93 Cr | ||
| Operating Profit | ₹1 Cr | ₹-14 Cr | ₹-30 Cr | ||
| OPM % | 1.0% | -16.0% | -47.0% | ||
| Other Income | ₹1 Cr | ₹1 Cr | ₹1 Cr | ||
| Depreciation | ₹7 Cr | ₹7 Cr | ₹7 Cr | ||
| Interest | ₹3 Cr | ₹3 Cr | ₹2 Cr | ||
| Profit Before Tax | ₹-9 Cr | ₹-24 Cr | ₹-38 Cr | ||
| Tax | ₹-9 Cr | ₹-24 Cr | ₹-38 Cr | ||
| Net Profit | ₹-19 Cr | ₹-19 Cr | ₹-31 Cr | ||
| EPS (₹) | -7.4 | -4.3 | -8.0 | ||
| Dividend Payout % | 0% | 0% | 0% |
Register free to see 2 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹15 Cr | ₹13 Cr | ₹16 Cr | ₹24 Cr | ||||||||
| Expenses | ₹24 Cr | ₹16 Cr | ₹20 Cr | ₹25 Cr | ||||||||
| Operating Profit | ₹-9 Cr | ₹-4 Cr | ₹-4 Cr | ₹-1 Cr | ||||||||
| OPM % | -55.9% | -29.3% | -24.9% | -4.5% | ||||||||
| Depreciation | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ||||||||
| Interest | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ||||||||
| Net Profit | ₹-9 Cr | ₹-4 Cr | ₹-4 Cr | ₹-2 Cr | ||||||||
| EPS (₹) | -1.9 | -1.6 | -1.7 | -0.6 |
Register free to see 8 more quarters.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹25 Cr | ₹25 Cr | ₹25 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹54 Cr | ₹63 Cr | ₹49 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹31 Cr | ₹25 Cr | ₹7 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹52 Cr | ₹83 Cr | ₹29 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹162 Cr | ₹196 Cr | ₹110 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹108 Cr | ₹110 Cr | ₹15 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹64 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹54 Cr | ₹71 Cr | ₹31 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹162 Cr | ₹196 Cr | ₹110 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 2 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2022 | ₹4 Cr | ₹-5 Cr | ₹1 Cr | — |
| Mar 2023 | ₹-37 Cr | ₹-25 Cr | ₹64 Cr | — |
| Mar 2024 | ₹-14 Cr | ₹0 Cr | ₹11 Cr | — |
| Mar 2025 |
Register free to see 2 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.